'Brilliant' and 'Steady' Jenkins Retiring From US FDA's Office of New Drugs
Executive Summary
Implementer of many drug review changes will leave in January after nearly 32 years of public service.
You may also be interested in...
Peter Stein Takes Short Path To Director Of US FDA Drug Office
An industry veteran, Stein has been with agency for only two years; Bob Temple becomes powerful OND "consultant."
Alzheimer's Guidance Coming From US FDA, Part Of Broader OND Reform
'Believe it or not, we don't have as many disease-specific guidances as you would suspect on the new drug side,' Commissioner Gottlieb says.
CDER’s 50 Open Leadership Posts Could Be Bigger Hiring Challenges After Trump Freeze
President Trump’s hiring freeze on civilian employees will exacerbate the Center for Drugs Evaluation & Research’s existing difficulties in recruiting and retaining qualified individuals. CDER is currently 591 positions under the hiring ceiling, include 50 open positions within CDER management.